JPH0296538A - Blood-collecting tube - Google Patents
Blood-collecting tubeInfo
- Publication number
- JPH0296538A JPH0296538A JP63247591A JP24759188A JPH0296538A JP H0296538 A JPH0296538 A JP H0296538A JP 63247591 A JP63247591 A JP 63247591A JP 24759188 A JP24759188 A JP 24759188A JP H0296538 A JPH0296538 A JP H0296538A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- glucose
- blood collection
- collection tube
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 claims abstract description 107
- 239000008280 blood Substances 0.000 claims abstract description 107
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims abstract description 12
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 10
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010876 biochemical test Methods 0.000 abstract description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 230000002414 glycolytic effect Effects 0.000 abstract description 14
- 230000034659 glycolysis Effects 0.000 abstract description 10
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 abstract description 4
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 abstract description 4
- 102000005548 Hexokinase Human genes 0.000 abstract description 3
- 108700040460 Hexokinases Proteins 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 abstract 1
- FZHXIRIBWMQPQF-SLPGGIOYSA-N aldehydo-D-glucosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FZHXIRIBWMQPQF-SLPGGIOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 8
- 230000008588 hemolysis Effects 0.000 description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229920003002 synthetic resin Polymers 0.000 description 6
- 239000000057 synthetic resin Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004673 fluoride salts Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229940045189 glucose-6-phosphate Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- -1 In addition Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009590 thymol turbidity test Methods 0.000 description 1
- 238000001721 transfer moulding Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000007666 vacuum forming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、血中の解糖による血糖の低下を速効的に阻止
することにより、血糖の初期値を維持し、かつ血糖検査
用検体と同一検体で同時に生化学検査が行なえる採血管
に関する。Detailed Description of the Invention (Field of Industrial Application) The present invention maintains the initial blood sugar level by rapidly inhibiting the drop in blood sugar due to glycolysis in the blood, and can be used as a sample for blood sugar testing. This invention relates to blood collection tubes that allow biochemical tests to be performed on the same specimen at the same time.
（従来の技術）
各種の臨床検査や病理学的研究のため力面液成分の測定
がなされている。これらの血液成分の測定の為に使用す
る採血管は、ガラス製もしくは合成樹脂製の採血管本体
と、該採血管本体の口部に使用するゴム製もしくは合成
樹脂製の栓体とからなり、これら採血管には、その底部
に、検査目的に応じて予め解糖阻止剤、抗凝固剤その他
の薬剤が粉末、顆粒又は水溶液の状態で収容されている
ものがある。(Prior Art) Surface fluid components are measured for various clinical tests and pathological research. The blood collection tube used to measure these blood components consists of a blood collection tube body made of glass or synthetic resin, and a stopper made of rubber or synthetic resin used at the mouth of the blood collection tube body. Some of these blood collection tubes have a glycolytic inhibitor, anticoagulant, or other drug stored in the bottom of the tube in the form of powder, granules, or aqueous solution, depending on the purpose of the test.
一般に、血液成分の検査を行う場合には、採血から測定
まである程度の時間を要する。特に、大病院や検査セン
ターなどでは、多数の検体を扱うため、検査業務の流れ
からいっても採血微少くとも室温下で数時間保存される
ことは避けられないし、場合によっては集配されてきた
検体にいたっては、更に長時間保存されろことがある。Generally, when testing blood components, a certain amount of time is required from blood collection to measurement. In particular, in large hospitals and testing centers, where large numbers of specimens are handled, it is unavoidable that blood samples are stored at room temperature for at least several hours due to the flow of testing operations, and in some cases, blood samples are collected and delivered. Samples may need to be stored for even longer periods of time.
血中のグルコース（血糖）の測定は、糖代謝状態の検査
のための重要な測定項目である。Measurement of blood glucose (blood sugar) is an important measurement item for testing the state of sugar metabolism.
血糖検査の場合、採血後の保存期間中に解糖により血糖
値が低下し易いので、その抑制を目的として解糖阻止剤
が収容された採血管が利用されている。従来、解糖阻止
剤としてフッ化塩、モノハロゲン化酢酸金属塩、クエン
酸およびＤ−マンノースなどが知られている。しかし、
これらの公知の解糖阻止剤には以下のような問題点があ
った。In the case of blood sugar testing, blood sugar levels tend to drop due to glycolysis during the storage period after blood collection, so blood collection tubes containing a glycolytic inhibitor are used to suppress this. Conventionally, fluoride salts, monohalogenated acetic acid metal salts, citric acid, D-mannose, and the like are known as glycolytic inhibitors. but,
These known glycolytic inhibitors have the following problems.
フッ化塩とモノハロゲン化酢酸金属塩は、それぞれエノ
ラーゼ、グリセルアルデヒド−３リン酸脱水素酵素の作
用を阻害することにより解糖阻止効果を有するが、これ
らの酵素は解糖系の下位の酵素であるため、阻止効果発
現までに時間がかかり、その間に血糖が少し低下するの
で速効性に乏しいという問題があった。しかし、阻止効
果が１度発現すると、それ以後は持続的に血糖は維持さ
れる。また、これらの解糖阻止剤は、血液検体に溶血を
おこす傾向があり、溶血すれば赤血球よりヘモグロビン
やカリウムが血漿中に漏出する。従って、この場合は、
これらの項目を正確に測定できない。さらに、比色法を
使用する血糖測定法においても誤差を与える。また、こ
れらの解糖阻止剤は、赤血球中の解糖系酵素の選択的な
阻害剤ではなく、酵素一般を阻害するため、血液検体中
の酵素成分の測定を行なえない。すなわち、これらの解
糖阻止剤を使用すると、血糖検査と共に、カリウムやナ
トリウムのような電解質や各種の酵素の検査のような、
所謂生化学検査とを、同一検体を使用して同時に出来な
いという問題点があった。Fluoride salts and monohalogenated acetic acid metal salts have a glycolytic blocking effect by inhibiting the actions of enolase and glyceraldehyde-3-phosphate dehydrogenase, respectively, but these enzymes inhibit lower-level glycolysis. Since it is an enzyme, it takes time for the inhibitory effect to appear, and during that time blood sugar levels drop slightly, so there is a problem that it is not fast-acting. However, once the inhibitory effect occurs, blood sugar levels are maintained continuously thereafter. Furthermore, these glycolytic inhibitors tend to cause hemolysis in blood samples, and when hemolysis occurs, hemoglobin and potassium leak from red blood cells into plasma. Therefore, in this case,
These items cannot be measured accurately. Furthermore, it also introduces errors in blood glucose measurement methods that use colorimetric methods. Furthermore, these glycolytic inhibitors are not selective inhibitors of glycolytic enzymes in red blood cells, but inhibit enzymes in general, and therefore enzyme components in blood samples cannot be measured. In other words, the use of these glycolytic inhibitors allows for tests such as blood sugar tests, electrolytes such as potassium and sodium, and various enzyme tests.
There was a problem in that so-called biochemical tests could not be performed simultaneously using the same specimen.
クエン酸は、ホスホフルクトキナーゼという解糖系の上
位の酵素を阻害するので、速効的な解糖阻止効果を示す
。しかし、クエン酸は、強酸性（ｐＨ１〜２）なので、
血液と混合されると血液のｐＨが酸性（ｐＨ４〜５）と
なり、赤血球が変性し溶血が激しくおこる。溶血すると
、６１述の７フ化塩やモノハロゲン化酢酸金属塩と同様
に、血糖と生化学検査を同一検体で同時に測定し得ない
。Citric acid inhibits phosphofructokinase, an enzyme at the upper level of glycolysis, and therefore exhibits a rapid glycolysis inhibiting effect. However, citric acid is strongly acidic (pH 1-2), so
When mixed with blood, the pH of the blood becomes acidic (pH 4 to 5), red blood cells are denatured, and hemolysis occurs violently. When hemolyzed, blood sugar and biochemical tests cannot be performed simultaneously on the same specimen, similar to the heptafluoride salt and monohalogenated metal acetate described in 61.
Ｄ−マンノースは、グルコースと同様にヘキソキナーゼ
の基質となるので、ヘキソキナーゼのグルコースの解糖
作用において、グルコースに競合する。このことにより
、解糖を阻止するため、速効性がある。また、溶血をお
こすことがないので、血糖と生化学検査と同一検体で一
応は、同時に行なえる。しかし、血糖測定法のうちで、
最近多く使用されているグルコース脱水素酵素を用いる
方法では、基質特異性の低い酵素が使われている場合、
グルコースだけでなく、異性体のＤ−マンノースも脱水
素される。Like glucose, D-mannose is a substrate for hexokinase, and thus competes with glucose in the glycolytic action of hexokinase on glucose. This prevents glycolysis and is therefore fast-acting. Furthermore, since hemolysis does not occur, blood sugar and biochemical tests can be performed simultaneously on the same specimen. However, among blood sugar measurement methods,
In the method using glucose dehydrogenase, which has been widely used recently, if an enzyme with low substrate specificity is used,
Not only glucose but also the isomer D-mannose is dehydrogenated.
そのため正の誤差の原因になるという問題点が残ってい
る。例えば、グルコースデヒドロゲナーゼの基質特異性
が低い場合、グルコース測定値が５００〜１０００”？
／ｄｉという値となり、正常値の５〜ｌＯ倍の正の誤差
を与える。Therefore, the problem remains that it causes a positive error. For example, if the substrate specificity of glucose dehydrogenase is low, the glucose measurement value will be between 500 and 1000"?
/di, giving a positive error of 5 to 10 times the normal value.
従って、フッ化塩、モノハロゲン化酢酸金属塩、クエン
酸またはＤ−マンノースなどが収容された採血管を使用
すると、血糖検査用検体と同一検体で同時に生化学検査
を正確に行うことができなかった。Therefore, if blood collection tubes containing fluoride salts, monohalogenated metal acetates, citric acid, or D-mannose are used, biochemical tests cannot be performed accurately on the same sample as the blood sugar test sample at the same time. Ta.
（発明が解決しようとする課題）
本発明は、上記従来の問題点を解決するものであり、そ
の目的とするところは、血中の解糖による血糖の低下を
速効的に阻止することにより、血糖の初期値を維持し、
かっ血糖検査用検体と同一検体で同時に生化学検査が、
共に正確に行なえる採血管を提供することにある。(Problems to be Solved by the Invention) The present invention solves the above-mentioned conventional problems, and its purpose is to immediately prevent the decrease in blood sugar due to glycolysis in the blood, thereby Maintains the initial blood sugar level,
Biochemical tests can be performed on the same sample as the blood sugar test sample at the same time.
The purpose of this invention is to provide a tube that allows blood collection to be carried out accurately.
（課題を解決するための手段）
本発明の採血管は、２−デオキシ−Ｄ−グル徴であり、
そのことにより上記目的が達成される。(Means for Solving the Problems) The blood collection tube of the present invention has a 2-deoxy-D-glue structure,
This achieves the above objective.
本発明の２−デオキシ−Ｄ−グルコース誘導体とは、２
−アミノ−２−デオキシ−〇−グルコース（以下、Ｄ−
グルコサミン）、または２−アセトアミド−２−デオキ
シ−Ｄ−グルコースなどを云う。The 2-deoxy-D-glucose derivative of the present invention is 2-deoxy-D-glucose derivative.
-amino-2-deoxy-〇-glucose (hereinafter referred to as D-
glucosamine) or 2-acetamido-2-deoxy-D-glucose.
使用される２−デオキシ−Ｄ−グルコースまたはその誘
導体の量は、血液検体１ ｍｌあたり、２．５〜１５１
１Ｐ、好ましくは５〜１０１１Ｐとなるように採血管に
加えられる。２．５ ”Ｐより少ないときは、速効的な
解糖阻止効果が不完全であり、１５”Ｐより多すぎると
、血液の浸透圧に異常をきたし溶血をおこすことがある
。The amount of 2-deoxy-D-glucose or its derivative used is 2.5 to 151 per ml of blood sample.
1P, preferably 5 to 1011P, is added to the blood collection tube. When it is less than 2.5"P, the rapid glycolysis inhibiting effect is incomplete, and when it is more than 15"P, the osmotic pressure of the blood may be abnormal and hemolysis may occur.
また、本発明の採血管に、更にヘパリン塩のような血液
抗凝固剤、または、トロンビンのような血液凝固促進剤
を加えることは任意である。Further, it is optional to further add a blood anticoagulant such as a heparin salt or a blood coagulation promoter such as thrombin to the blood collection tube of the present invention.
本発明の採血管は、次のようにして製造される。採血管
本体の材質は、ガラス製、合成樹脂製のどちらでもよい
。合成樹脂製のものは、射出成形法によって製造される
のが最も効率が良く、その他には、ブロー成形、圧縮成
形、トランスファー成形、真空成形、キャスト成形等の
適宜の方法によって製造される。The blood collection tube of the present invention is manufactured as follows. The material of the blood collection tube body may be either glass or synthetic resin. Those made of synthetic resin are most efficiently manufactured by injection molding, and other suitable methods such as blow molding, compression molding, transfer molding, vacuum forming, and cast molding are also suitable.
この採血管本体に、２−デオキシ−Ｄ−グルコースまた
はその誘導体（以下、該薬剤とする）が、粉末、顆粒ま
たは水溶液の状態で収容された後、ゴム製もしくは合成
樹脂製の栓体で閉蓋される。また、該薬剤の粉末または
顆粒を適当な溶媒に分散させたものを、ガラスや合成樹
脂製のペレットやビーズにコーティングし、このペレッ
トやビーズを採血管本体に収容してもよい。また、上記
の溶媒に分散したものを、採血管本体内壁にコーティン
グしてもよい。After 2-deoxy-D-glucose or its derivative (hereinafter referred to as the drug) is contained in the blood collection tube body in the form of powder, granules, or aqueous solution, it is closed with a stopper made of rubber or synthetic resin. Covered. Alternatively, pellets or beads made of glass or synthetic resin may be coated with powder or granules of the drug dispersed in a suitable solvent, and the pellets or beads may be housed in the blood collection tube body. Alternatively, a dispersion in the above solvent may be coated on the inner wall of the blood collection tube body.
また、採血管は常圧のものばかりでなく、該薬剤が収容
された後、内部を減圧にすることにより所謂真空採血管
としてもよい。Further, the blood collection tube is not limited to one having normal pressure, and may be a so-called vacuum blood collection tube by reducing the pressure inside the tube after the drug is contained therein.
また、該採血管内部に血漿（血清）分離剤を収容してお
くことは任意である。Further, it is optional to store a plasma (serum) separation agent inside the blood collection tube.
本発明の採血管の使用方法は、上記のようにして製造さ
れた採血管Ｉζ、被採血者からの血液を加えた後、遠心
分離して血漿または血清分両を得、それを各種の検査の
検体として使用する。The method of using the blood collection tube of the present invention is to add blood from a blood sample to the blood collection tube Iζ manufactured as described above, and then centrifuge it to obtain plasma or serum fraction, which is then used for various tests. used as a specimen.
（作 用）
採血管に収容されている２−デオキシ−Ｄ−グルコース
またはその誘導体は解糖系のへキソキナーゼによるグル
コース→グルコース′−６−リン酸の反応において、Ｄ
−グルコースと競合する。そのため、グルコース−６−
リン酸の生成が阻害され、赤血球膜中へ入るグルコース
−６−リン酸の量が極端に減少する。っまり赤面ＲＭの
糖輸送機構が阻害される。このよう番こ、解糖系が初期
の段階で阻害されるため解糖阻止の速効性を有する。(Function) 2-deoxy-D-glucose or its derivatives contained in the blood collection tube is a D
-Competes with glucose. Therefore, glucose-6-
Phosphate production is inhibited, and the amount of glucose-6-phosphate that enters the red blood cell membrane is extremely reduced. The sugar transport mechanism of RM is inhibited. This method inhibits the glycolytic system at an early stage, so it has a rapid effect on blocking glycolysis.
また、２−デオキシ−Ｄ−グルコースまたはその誘導体
は、Ｄ−マンノースのように基質特異性の低いグルコー
ス脱水素酵素の基質でないノテ、クルコース値の正の誤
差を与えることがない。In addition, 2-deoxy-D-glucose or its derivatives do not give a positive error in the glucose value, unlike D-mannose, which is not a substrate for glucose dehydrogenase with low substrate specificity.
また、２−デオキシ−Ｄ−グルコースまたはその誘導体
は、血液１ ｍｌあたりＩｓ”Ｐ以下で使用すれば、血
液検体を溶血させることもなく、生化学検査に悪影響を
ひき起こさない。Furthermore, if 2-deoxy-D-glucose or its derivatives are used at less than Is''P per ml of blood, it will not cause hemolysis of the blood specimen and will not cause any adverse effects on biochemical tests.
（実施例） 以下に本発明の実施例につき説明する。(Example) Examples of the present invention will be described below.
実施例１
内径が１．５１、長さが１１国のブリエチレンテレツク
レート製の採血管本体を作り、その中にＤ−グルコサミ
ン３０．０ ”？およびヘパリンＮａ９０７５を収容し
た後、ブチルゴム製の栓体で閉蓋して採血管とした。Example 1 A blood collection tube body with an inner diameter of 1.51 mm and a length of 11 mm made of ethylene terecrate was made, and after accommodating D-glucosamine 30.0"? and heparin Na9075 therein, a stopper made of butyl rubber was made. The tube was closed with the body and used as a blood collection tube.
この採血管に健常人からの新鮮面６ ｍｌを加え、閉蓋
後、転倒混和した。これを室温で、採血後４時間放置し
た。6 ml of fresh blood from a healthy individual was added to this blood collection tube, and after the lid was closed, the tube was mixed by inversion. This was left at room temperature for 4 hours after blood collection.
次に３００ Ｏｒｐｍで５分間遠心分離し、血漿を採取
した。この血漿を使用して、次に示す２０項目の生化学
検査と血糖の測定を行った。Next, the plasma was collected by centrifugation at 300 rpm for 5 minutes. Using this plasma, the following 20 biochemical tests and blood sugar measurements were performed.
チモール混濁試験（ＴＴＴ）、硫酸亜鉛試験（ＺＴＴ）
、アルカリ性７オス７アターゼ（ＡＬＰ）、ＧＯＴ、Ｇ
ＰＴ、ＬＤＨ，ロイシンアミノペプチダーゼ（ＬＡＰ）
、ｒ−ＧＴＰ 、クレアチン７オス７オキナーゼ（ＣＰ
Ｋ）、尿酸（ＵＡ）、β−リポ蛋白（β−ＬＰ）、血ｌ
ｌＩ総蛋白（ＴＰ）、アミラーゼ（ＡＭＹ）、クレアチ
ニン（ＣＲＴＮ）、血清コリンエステラーゼ（ＣｈＥ）
。Thymol turbidity test (TTT), zinc sulfate test (ZTT)
, alkaline 7 male 7 atase (ALP), GOT, G
PT, LDH, leucine aminopeptidase (LAP)
, r-GTP, creatine 7-mose 7-okinase (CP
K), uric acid (UA), β-lipoprotein (β-LP), blood
lI total protein (TP), amylase (AMY), creatinine (CRTN), serum cholinesterase (ChE)
.
ビリルビン（Ｂｉｌ）、アルブミン（Ａｌｂ）、Ｎａ、
に、Ｆｅ
血糖は、協和メデックス社製のグルコース定量試薬［デ
タミナーＧＬ−ＲＪを用いて、グルコースデヒドロゲナ
ーゼ法によって測定した。Bilirubin (Bil), albumin (Alb), Na,
In addition, Fe blood sugar was measured by the glucose dehydrogenase method using a glucose quantitative reagent [Determiner GL-RJ manufactured by Kyowa Medex Co., Ltd.].
原理は以下の通りである。The principle is as follows.
β−Ｄ−グルコース Ｄ−グルコ／
−１−ラフ）ン上記の酵素反応で生じるＮＡＤＰＨ３を
、反応速度（レートアッセイ）法により３４０ ｎｍで
測定した。β-D-glucose D-gluco/
-1-Raf) NADPH3 produced in the above enzymatic reaction was measured at 340 nm by a rate assay method.
実施例２
実施例１の採血管本体に、Ｄ−グルコサミンに
６０、０１”？およびトロンビン３０口を収容後、ブチ
ルゴム族の栓体で閉蓋して、採血管とした。Example 2 D-glucosamine 60.01"? and 30 ports of thrombin were housed in the blood collection tube body of Example 1, and the tube was closed with a butyl rubber stopper to obtain a blood collection tube.
この採血管に健常人からの新鮮面６ｍｌを加え、閉蓋後
、転倒混和した。6 ml of fresh blood from a healthy person was added to this blood collection tube, and after the lid was closed, the tube was mixed by inversion.
これを室温で、採血後４時間放置した。次に、３０００
ｒｐｍで５分間遠心分離し、血清を採取した。この血
清を使用して、実施例１と同様の項目について測定を行
った。This was left at room temperature for 4 hours after blood collection. Next, 3000
Serum was collected by centrifugation at rpm for 5 minutes. Using this serum, the same items as in Example 1 were measured.
比較例１
Ｄ−グルコサミン６、０ ！およびヘパリンＮａ ９０
ｅ巳を収容して採血管とした以外は、実施例１と同様に
して２０項目の生化学検査と血糖の測定を行った。Comparative Example 1 D-glucosamine 6.0! and heparin Na 90
20 biochemical tests and blood sugar measurements were performed in the same manner as in Example 1, except that an eel was housed and used as a blood collection tube.
比較例２
Ｄ−グルコサミン１２０”ｌおよびトロンビン３０口を
収容して採血管とした以外は、実施例２と同様にして２
０項目の生化学検査と血糖の測定を行った。Comparative Example 2 A blood collection tube was prepared in the same manner as in Example 2, except that 120"L of D-glucosamine and 30 ports of thrombin were contained in the blood collection tube.
0 biochemical tests and blood sugar measurements were performed.
比較例３
Ｄ−マンノース３０．０ηおよびヘパリンＮａ９０萱を
収容して採血管とした以外は、実施例１と同様にして２
０項目の生化学検査と血糖の測定を行った。Comparative Example 3 A blood collection tube was prepared in the same manner as in Example 1, except that 30.0η of D-mannose and 90.0η of heparin Na were contained in the blood collection tube.
0 biochemical tests and blood sugar measurements were performed.
参考例
に
■トロンビン３０Ｐ：Ｊを収容して採血管としたこと■
採血管に血液を加え、血液の凝固後すぐに遠心分離して
血清を採取したこと以外は、実施例２と同様にして２０
項目の生化学検査と血糖の測定を行った。As a reference example, ■Thrombin 30P:J was housed and used as a blood collection tube■
The procedure for 20 days was carried out in the same manner as in Example 2, except that blood was added to the blood collection tube, and immediately after the blood coagulated, it was centrifuged to collect serum.
Itemized biochemical tests and blood sugar measurements were performed.
この参考例は、それぞれの測定項目における初期値（ブ
ランク）を測定するために行ったものである。This reference example was conducted to measure initial values (blanks) for each measurement item.
叙上の各実施例、比較例および参考例における生化学検
査値および血糖測定値を第１表に示した。Table 1 shows the biochemical test values and blood sugar measurement values for each of the Examples, Comparative Examples, and Reference Examples described above.
第 １ 表
（以下余白）
第１表より、実施例１〜２は、生化学検査２０項目およ
び血糖の測定値において参考例（ブランク）と有意差は
ない。Table 1 (blank below) From Table 1, Examples 1 and 2 have no significant difference from the reference example (blank) in the 20 biochemical test items and blood sugar measurement values.
比較例１はＤ−グルコサミンの使用量が少ないため、少
し血糖値の低下がみられた。比較例２はＤ−グルコサミ
ンの量が多すぎるので、少し溶血し、ＬＤＨ１電解質（
Ｎａ、Ｋ）の測定値に影響を与えた。In Comparative Example 1, since the amount of D-glucosamine used was small, a slight decrease in blood sugar level was observed. In Comparative Example 2, the amount of D-glucosamine was too large, resulting in slight hemolysis and LDH1 electrolyte (
This affected the measured values of Na, K).
Ｊｔ［［Ｊ３＃′ｉＤ−マンノースがグリコースデヒド
ロゲナーゼにより分解され、血糖が正常値の５倍という
異常高値を示した。Jt[[J3#'iD-mannose was decomposed by glycose dehydrogenase, resulting in an abnormally high blood sugar level five times the normal value.
（発明の効果）
本発明の採血管は、２−デオキシ−Ｄ−グルコースまた
はその誘導体が収容されているので。(Effects of the Invention) The blood collection tube of the present invention contains 2-deoxy-D-glucose or a derivative thereof.
採血された血中の解糖系が初期の段階で阻害されるため
、血中の血糖の低下を速効的に阻止することにより、血
糖の初期値を室温下で少くとも４時１ｆｌｊ維持し得、
かつ血液を溶血させることもなく、また酵素一般の酵素
作用を阻害することもないので、生化学検査のための検
体調製にも適している。Since the glycolytic system in the collected blood is inhibited at an early stage, the initial value of blood sugar can be maintained at room temperature for at least 4:00 pm by quickly blocking the drop in blood sugar. ,
Furthermore, since it does not cause hemolysis of blood or inhibit the enzyme action of general enzymes, it is also suitable for preparing specimens for biochemical tests.
すなわち、血糖検査用検体と同一検体で同時に生化学検
査が行なえる検体をＥ！することができる。In other words, the E! can do.
また、２−デオキシ−Ｄ−グルコースまたはその誘導体
は、Ｄ−マンノースと遮って、基質特異性の低いグルコ
ース脱水素酵素の基質にならないので、グルコース脱水
素酵素を使用する血糖測定法に使用されたとき、正確な
血糖値を得ることができる。In addition, 2-deoxy-D-glucose or its derivatives intercepts D-mannose and does not become a substrate for glucose dehydrogenase, which has low substrate specificity, so it has been used in blood glucose measurement methods that use glucose dehydrogenase. When you can get accurate blood sugar levels.
上述のように、本発明の採血管を使用すると、血糖と生
化学検査測定を同一検体で同時に正確に行なえる検体を
調製できるので、例えば、患者のような被採血者の血液
を無駄にすることなく■効に使用できるので、被採血者
の採血による精神的および肉体的負担を軽減できる。As mentioned above, by using the blood collection tube of the present invention, it is possible to prepare a sample in which blood glucose and biochemical test measurements can be performed simultaneously and accurately on the same sample, thereby eliminating the need to waste blood from a blood sample such as a patient. ■Since it can be used effectively without any problems, the mental and physical burden of blood collection on the blood sample recipient can be reduced.
血糖と共に多項目の生化学検査を同一検体で同時に測定
できるので、多項目自動分析機にかけることができ、作
業性や効率が上がる。更に、検査に必要な試験管や測定
機器も減らし得るので経済的でもある。Since blood sugar and multiple biochemical tests can be measured simultaneously on the same sample, it can be run on a multi-item automatic analyzer, improving workability and efficiency. Furthermore, it is also economical because the number of test tubes and measuring equipment required for testing can be reduced.
以 上that's all
Claims (1)
収容されていることを特徴とする採血管1) A blood collection tube containing 2-deoxy-D-glucose or a derivative thereof
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63247591A JP2506992B2 (en) | 1988-09-30 | 1988-09-30 | Blood collection tube |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63247591A JP2506992B2 (en) | 1988-09-30 | 1988-09-30 | Blood collection tube |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0296538A true JPH0296538A (en) | 1990-04-09 |
| JP2506992B2 JP2506992B2 (en) | 1996-06-12 |
Family
ID=17165784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63247591A Expired - Fee Related JP2506992B2 (en) | 1988-09-30 | 1988-09-30 | Blood collection tube |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2506992B2 (en) |
-
1988
- 1988-09-30 JP JP63247591A patent/JP2506992B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2506992B2 (en) | 1996-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lum et al. | A comparison of serum versus heparinized plasma for routine chemistry tests | |
| Coe | Postmortem chemistry update emphasis on forensic application | |
| Beutler et al. | Improved method for measuring galactose-1-phosphate uridyl transferase activity of erythrocytes | |
| CN101101293B (en) | Suspension medium for red blood cells | |
| JP2542780B2 (en) | Enzyme neutralization of heparin | |
| Gerard et al. | Characterization of creatinine error in ketotic patients: a prospective comparison of alkaline picrate methods with an enzymatic method | |
| JP3075751B2 (en) | Inhibitors for anticoagulant pretreatment of blood samples | |
| Czapek et al. | Platelet dysfunction in glycogen storage disease type I | |
| US20180027802A1 (en) | Composition and use of substances for the in vitro stabilization of glucose, lactate and homocysteine in blood | |
| RU2595806C2 (en) | Method of determining oxidative modification of fibrinogen in blood plasma by content of carbonyl groups in fibrinous clot | |
| Zoppi et al. | Measurement of ionized magnesium with AVL 988/4 electrolyte analyzer: preliminary analytical and clinical results | |
| Zehnder et al. | Clinical use of coagulation tests | |
| JPH0296538A (en) | Blood-collecting tube | |
| Redetzki et al. | Differences between serum and plasma osmolalities and their relationship to lactic acid values | |
| US6368785B1 (en) | Anti-coagulation of blood, plasma or synovial fluid products using iso-citrate | |
| Er et al. | Selected analyte values in serum versus heparinized plasma using the SYNCHRON LX PRO assay methods/instrument | |
| US6261796B1 (en) | Method and kit for measuring mitochondrial activity | |
| JP5425062B2 (en) | Method for measuring glycoalbumin and the like using a control sample containing D-mannitol | |
| Ganapathy et al. | L Glyceraldehyde-Will it be an effective Antiglycolytic Agent | |
| Vucijak-Grgurevic et al. | Significance of nitric oxyde saliva concentration of the patients with renal failure on hemodialysis | |
| US20040048324A1 (en) | Control serum for dry analytical element | |
| Devgun | Delay in centrifugation and measurement of serum constituents in normal subjects | |
| JP4163056B2 (en) | Additive composition for measuring blood insulin concentration and blood collection tube containing the same | |
| JP2019002821A (en) | Blood drawing tube | |
| WO1995014788A1 (en) | Blood coagulation retardants and devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |